Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Remuzzi

Showing results (141-150 of 894) with videos related to

Pageof 90
Sort By:
Nephron|April 21, 2016
Progression, Remission and Regression of Chronic Renal DiseasesMonica Cortinovis, Piero Ruggenenti, Giuseppe Remuzzi
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 1, 2021
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatmentMarina Noris, Erica Daina, Giuseppe Remuzzi
Nature Reviews. Nephrology|May 5, 2010
The RAAS in the pathogenesis and treatment of diabetic nephropathyPiero Ruggenenti, Paolo Cravedi, Giuseppe Remuzzi
Lancet (London, England)|April 14, 2009
Sirolimus to replace calcineurin inhibitors? Too early yetPaolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi
Nephron|September 20, 2016
Should We Still Believe in Randomized Controlled Trials in Nephrology?Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
Current Opinion in Pharmacology|May 9, 2017
ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal diseaseNorberto Perico, Piero Ruggenenti, Giuseppe Remuzzi
Kidney International|April 5, 2003
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countriesArrigo Schieppati, Norberto Perico, Giuseppe Remuzzi
Current Opinion in Organ Transplantation|December 10, 2019
Update on mesenchymal stromal cell studies in organ transplant recipientsSonia Fiori, Giuseppe Remuzzi, Federica Casiraghi
Nephron|March 24, 2020
Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin BlockadeLuca Perico, Ariela Benigni, Giuseppe Remuzzi
Kidney International|January 7, 2020
Does MRI trump pathology? A new era for staging and monitoring of kidney fibrosisAnna Caroli, Andrea Remuzzi, Giuseppe Remuzzi
Pageof 90

Showing results (141-150 of 894) with videos related to

Sort By:
Pageof 90
Nephron|April 21, 2016
Progression, Remission and Regression of Chronic Renal DiseasesMonica Cortinovis, Piero Ruggenenti, Giuseppe Remuzzi
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 1, 2021
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatmentMarina Noris, Erica Daina, Giuseppe Remuzzi
Nature Reviews. Nephrology|May 5, 2010
The RAAS in the pathogenesis and treatment of diabetic nephropathyPiero Ruggenenti, Paolo Cravedi, Giuseppe Remuzzi
Lancet (London, England)|April 14, 2009
Sirolimus to replace calcineurin inhibitors? Too early yetPaolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi
Nephron|September 20, 2016
Should We Still Believe in Randomized Controlled Trials in Nephrology?Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
Current Opinion in Pharmacology|May 9, 2017
ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal diseaseNorberto Perico, Piero Ruggenenti, Giuseppe Remuzzi
Kidney International|April 5, 2003
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countriesArrigo Schieppati, Norberto Perico, Giuseppe Remuzzi
Current Opinion in Organ Transplantation|December 10, 2019
Update on mesenchymal stromal cell studies in organ transplant recipientsSonia Fiori, Giuseppe Remuzzi, Federica Casiraghi
Nephron|March 24, 2020
Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin BlockadeLuca Perico, Ariela Benigni, Giuseppe Remuzzi
Kidney International|January 7, 2020
Does MRI trump pathology? A new era for staging and monitoring of kidney fibrosisAnna Caroli, Andrea Remuzzi, Giuseppe Remuzzi
Pageof 90